Researchers developed a DNA aptamer that specifically targets Coenzyme A, enabling easy and accurate detection in cells. This technology is more specific and simpler than current methods, supporting diagnostics, research, and treatments for diseases involving CoA imbalance.
Background
The field of biochemical research and medical diagnostics increasingly recognizes the critical role of Coenzyme A (CoA) in various cellular processes and its dysregulation in numerous diseases, such as PKAN and CoPAN. Accurate detection and imaging of CoA are essential for understanding its distribution and concentration within mammalian cells, facilitating advancements in diagnostics, therapeutics, and drug discovery. As CoA is fundamental to metabolism and cellular function, reliable tools to monitor its levels are indispensable for both basic research and the development of treatments targeting metabolic disorders.
Current approaches to CoA detection face significant challenges that impede their effectiveness and broader application. High-performance liquid chromatography-mass spectrometry (HPLC-MS), while precise, requires complex sample preparation, is not well-suited for detecting low concentrations of CoA, and demands a high level of technical expertise. Commercial CoA detection kits often suffer from limited specificity and compatibility with diverse sample types, reducing their utility in varied experimental settings. Additionally, protein-based CoA biosensors are hindered by stability issues and are prone to interference, complicating their use in dynamic biological environments. These limitations underscore the need for more robust, specific, and user-friendly methods for CoA detection and imaging.
Technology description
The technology introduces a novel DNA aptamer specifically engineered to bind Coenzyme A (CoA), developed through a collaboration between The University of Texas at Austin and the University of Illinois at Urbana-Champaign. This single-stranded DNA molecule adopts a three-dimensional configuration tailored to CoA’s structure, enabling precise detection and imaging of CoA within mammalian cells and lysates. Utilizing structure-switching SELEX methodology, the aptamer functions as a highly selective “turn-on” sensor system that incorporates fluorophores and quenchers. This design allows for various detection methods, including fluorescence assays, microscopy, and gel electrophoresis, facilitating the visualization of CoA distribution and the quantitative measurement of its concentrations. The technology is versatile, supporting applications in diagnostics, therapeutics, research, and drug screening, and is particularly valuable for studying diseases associated with CoA dysregulation such as PKAN and CoPAN.
This technology distinguishes itself from existing CoA detection methods through several key advantages. Unlike HPLC-MS, it requires simpler sample preparation, effectively handles low CoA concentrations and similar compounds, reduces matrix effects, and demands less technical expertise. Compared to commercial CoA detection kits, it offers superior specificity and broader sample compatibility. Additionally, it surpasses protein-based CoA biosensors by providing enhanced stability, a simpler development process, and reduced interference. The aptamer system’s ability to employ multiple detection techniques and its compatibility across various organisms further set it apart, making it a significant advancement in CoA detection and monitoring with broad implications for both research and therapeutic applications.
Benefits
- Simpler sample preparation compared to HPLC-MS
- Higher specificity and broader sample compatibility than commercial kits
- Enhanced stability and reduced interference over protein-based biosensors
- Supports multiple detection methods, including fluorescence assays, microscopy, and gel electrophoresis
- Enables visualization and quantitative measurement of CoA in mammalian cells
- Applicable in diagnostics, therapeutics, research, and drug screening
- Substantial market potential in drug discovery, scientific research, and metabolic disease treatment
Commercial applications
- Diagnostic CoA detection kits
- Metabolic disease diagnostics
- Drug discovery assays
- Cellular process research tools
- Molecular probe development
Opportunity
The University of Texas at Austin is seeking an industry partner to license this technology. A DNA aptamer specifically designed to bind Coenzyme A (CoA) using structure-switching SELEX. This single-stranded molecule forms a three-dimensional structure complementary to CoA and incorporates fluorophores and quenchers for fluorescence-based detection. Compatible with mammalian cells and lysates, it enables fluorescence assays, microscopy, and gel electrophoresis. It offers enhanced specificity, simpler sample preparation, and broader compatibility compared to traditional methods, facilitating precise CoA imaging and quantification for diagnostics, research, and therapeutic applications.
Intellectual property
A U.S. provisional patent application has been filed.
